This research not only helps with the identification of variables that attenuate the impact of side effects of chemotherapy on the quality of life of cancer survivors but also offers a recommendation that medical professionals can use to immediately and positively enhance patient prognosis. Additionally, providing patients more information about potential consequences of medications could contribute to the development of primary, secondary, and tertiary preventions. Excessive alcohol consumption is a risk factor for cancer onset and recurrence; however, moderate consumption can have positive effects to counteract chemotherapy side effects during treatment. The key is moderation and education on use vs abuse. Medical and other health professionals should help patients diagnosed with cancer in this process, by discussing how alcohol is related to cancer with patient.
It is known that cancer and chemotherapy could affect a patient’s cognitive abilities, and therefore, patients should be informed of potential side effects in order to develop compensatory skills to cope with the diagnosis and the adverse effects of therapeutic intervention. There are a variety of treatments available to help patients’ cope, including medical treatments, such as use of ginkgo biloba,48 nonmedical cognitive therapy protocols (memory and attention behavioral training or computerized training),49–51 restorative therapies (choosing calming experiences or Tibetan mediations),52,53 and coping strategy therapies (relaxation, self-awareness, or compensatory strategies).49–51 All have been successful in improving patient outcomes. Interventions will vary by location based on availability and regional cultural practice, but local American Cancer Society chapters are established throughout US, and PR will provide support groups and information to patients. An increase in awareness among health care professionals and patients is needed to encourage the development of interventions that can help cancer patients manage medication side effects and long-term consequences in order to improve their outcome and overall well-being.
Additionally, we thank Siobahn Evans and Dianna Nguyen for editing the article.
Conceived and designed the experiments: SFA and CEC. Analyzed the data: SFA and CEC. Wrote the first draft of the manuscript: CEC. Contributed to the writing of the manuscript: SFA, CEC, and RD. Agree with manuscript results and conclusions: SFA, CEC, and RD. Jointly developed the structure and arguments for the paper: SFA and CEC. Made critical revisions and approved final version: SFA and RD. All authors reviewed and approved of the final manuscript.
Carmen E. Couvertier-Lebron1, Rachel Dove2 and Summer F. Acevedo3
1Psychology Program, Ponce School of Medicine and Health Sciences, Ponce, Puerto Rico. 2Department of Psychiatry, UT Southwestern Medical Center, Dallas, TX, USA. 3Instructor, Department of Psychiatry, UT Southwestern Medical Center, Dallas, TX, USA.
1. Williams AR, Mowlazadeh B, Sisler L, Williams PD. Self-reported assessment of symptoms and self-care within a cohort of U.S. veterans during outpatient care for cancer. Clin J Oncol Nurs. 2015;19:595–602.
2. World Cancer Research Fund/American Institute for Cancer Research. Food, Nutrition, Physical Activity and the Prevention of Cancer: A Global Prospective; 2007. Available at: http://www.dietandcancerreport.org/cancerresourcecenter/ downloads/SecondExpertReportfull.pdf
3. American Cancer Society. Cancer Facts & Figures. Atlanta, GA: American Cancer Society; 2016.
4. Siegel R, Naishadham D, Jemal A. Cancer statistics for Hispanics/Latinos, 2012. CA Cancer J Clin. 2012;62:283–298.
5. Ortiz KJ, Perez J, Torres M. El cancere de mama en Puerto Rico. San Juan, PR: Department of Health, Central Cancer Registry of Puerto Rico; 2008.
6. Puerto Rico Department of Health. Central Cancer Registry. Database. Vol 1; 2008.
7. Ho GY, Figueroa-Valles NR, De La Torre-Feliciano T, et al. Cancer disparities between mainland and island Puerto Ricans. Rev Panam Salud Publica. 2009; 25:394–400.
8. Bosetti C, La Vecchia C. Cancer mortality in Latin America: implications for prevention. Rev Panam Salud Publica. 2005;18:1–4.
9. Choi SM, Lee SH, Yang YS, Kim BC, Kim MK, Cho KH. 5-fluorouracil-induced leukoencephalopathy in patients with breast cancer. J Korean Med Sci. 2001;16:328–334.
10. Myers JS, Sousa VD, Donovan HS. Predictors of self-reported memory problems in patients with ovarian cancer who have received chemotherapy. Oncol Nurs Forum. 2010;37:596–603.
11. Ferguson RJ, McDonald BC, Saykin AJ, Ahles TA. Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy. J Clin Oncol. 2007;25:3866–3870.
12. Wefel JS, Saleeba AK, Buzdar AU, Meyers CA. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer. 2010;116:3348–3356.
13. Acevedo SF. Why, after chemotherapy, is it necessary to assess memory using translational testing? Breast Cancer (Auckl). 2012;6:181–190.
14. Inagaki M, Yoshikawa E, Matsuoka Y, et al. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer. 2007;109:146–156.
15. Deprez S, Amant F, Smeets A, et al. Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol. 2012;30:274–281.
16. Kesler S, Hadi Hosseini SM, Heckler C, et al. Cognitive training for improving executive function in chemotherapy-treated breast cancer survivors. Clin Breast Cancer. 2013;13:299–306.
17. Morean DF, O’Dwyer L, Cherney LR. Therapies for cognitive deficits associated with chemotherapy for breast cancer: a systematic review of objective outcomes. Arch Phys Med Rehabil. 2015;96(10):1880–1897.
18. Von Ah D, Habermann B, Carpenter JS, Schneider BL. Impact of perceived cognitive impairment in breast cancer survivors. Eur J Oncol Nurs. 2013;17:236–241.
19. Wefel JS, Vidrine DJ, Marani SK, et al. A prospective study of cognitive function in men with non-seminomatous germ cell tumors. Psychooncology. 2014;23: 626–633.
20. Nelson CJ, Nandy N, Roth AJ. Chemotherapy and cognitive deficits: mechanisms, findings, and potential interventions. Palliat Support Care. 2007;5:273–280.
21. Dietrich J, Han R, Yang Y, Mayer-Pröschel M, Noble M. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol. 2006;5:22.
22. Ayala-Feliciano M, Pons-Valerio JJ, Pons-Madera J, Acevedo SF. The relationship between visuospatial memory and coping strategies in breast cancer survivors. Breast Cancer (Auckl). 2011;5:117–130.
23. Singletary SE. Rating the risk factors for breast cancer. Ann Surg. 2003;237: 474–482.
24. Wright RM, McManaman JL, Repine JE. Alcohol-induced breast cancer: a proposed mechanism. Free Radic Biol Med. 1999;26:348–354.
25. Singletary KW, Gapstur SM. Alcohol and breast cancer: review of epidemiologic and experimental evidence and potential mechanisms. JAMA. 2001;286: 2143–2151.
26. Boffetta P, Hashibe M. Alcohol and cancer. Lancet Oncol. 2006;7:149–156.
27. Naimi TS, Nelson DE, Brewer RD. The intensity of binge alcohol consumption among U.S. adults. Am J Prev Med. 2010;38:201–207.
28. Cokkinides VE, Bandi P, Siegel RL, Jemal A. Cancer-related risk factors and preventive measures in US Hispanics/Latinos. CA Cancer J Clin. 2012;62:353–363.
29. Allison PJ. Alcohol consumption is associated with improved health-related quality of life in head and neck cancer patients. Oral Oncol. 2002;38:81–86.
30. Rose AK, Hardman CA, Christiansen P. The effects of a priming dose of alcohol and drinking environment on snack food intake. Appetite. 2015;95:341–348.
31. Barnett GC, Shah M, Redman K, Easton DF, Ponder BA, Pharoah PD. Risk factors for the incidence of breast cancer: do they affect survival from the disease? J Clin Oncol. 2008;26:3310–3316.
32. Allemani C, Berrino F, Krogh V, et al. Do pre-diagnostic drinking habits influence breast cancer survival? Tumori. 2011;97:142–148.
33. Centre for Addiction & Mental Health. Alcohol and Cancer: Best Advice; 2007.
34. Brilsin RW. Back-translation for cross-cultural research. J Cross Cult Psychol. 1970;3:185–216.
35. Cha ES, Kim KH, Erlen JA. Translation of scales in cross-cultural research: issues and techniques. J Adv Nurs. 2007;58:386–395.
36. Roa CR, Sinharay S. Handbook of Statistics: Psychometrics. Amsterdam: Elsevier; 2007.
37. Seigers R, Schagen SB, Beerling W, et al. Long-lasting suppression of hippocampal cell proliferation and impaired cognitive performance by methotrexate in the rat. Behav Brain Res. 2008;186:168–175.
38. Seigers R, Schagen SB, Coppens CM, et al. Methotrexate decreases hippocampal cell proliferation and induces memory deficits in rats. Behav Brain Res. 2009; 201:279–284.
39. Koppelmans V, Breteler MM, Boogerd W, Seynaeve C, Gundy C, Schagen SB. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. J Clin Oncol. 2012;30:1080–1086.
40. Nelson WL, Suls J. New approaches to understand cognitive changes associated with chemotherapy for non-central nervous system tumors. J Pain Symptom Manage. 2013;46:707–721.
41. Comeau TB, Epstein JB, Migas C. Taste and smell dysfunction in patients receiving chemotherapy: a review of current knowledge. Support Care Cancer. 2001; 9:575–580.
42. Hoskins CN. Breast cancer treatment-related patterns in side effects, psychological distress, and perceived health status. Oncol Nurs Forum. 1997;24:1575–1583.
43. Rehwaldt M, Wickham R, Purl S, et al. Self-care strategies to cope with taste changes after chemotherapy. Oncol Nurs Forum. 2009;36:E47–E56.
44. Gee C. Does alcohol stimulate appetite and energy intake? Br J Community Nurs. 2006;11:298–302.
45. Franks HM, Roesch SC. Appraisals and coping in people living with cancer: a meta-analysis. Psychooncology. 2006;15:1027–1037.
46. Fastame MC, Penna MP. Does social desirability confound the assessment of self-reported measures of well-being and metacognitive efficiency in young and older adults? Clin Gerontol. 2012;35:239–256.
47. Collins RL, McNair LD. Minority Women and Alcohol Use. National Institute of Health: National Institute of Drug Alcohol Abuse and Alcoholism (NIAAA); 2003.
48. Barton DL, Burger K, Novotny PJ, et al. The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9. Support Care Cancer. 2013;21:1185–1192.
49. Ercoli LM, Castellon SA, Hunter AM, et al. Assessment of the feasibility of a rehabilitation intervention program for breast cancer survivors with cognitive complaints. Brain Imaging Behav. 2013;7:543–553.
50. Ferguson RJ, Ahles TA, Saykin AJ, et al. Cognitive-behavioral management of chemotherapy-related cognitive change. Psychooncology. 2007;16:772–777.
51. Ferguson RJ, McDonald BC, Rocque MA, et al. Development of CBT for chemotherapy-related cognitive change: results of a waitlist control trial. Psychooncology. 2012;21:176–186.
52. Cimprich B. Development of an intervention to restore attention in cancer patients. Cancer Nurs. 1993;16:83–92.
53. Milbury K, Chaoul A, Biegler K, et al. Tibetan sound meditation for cognitive dysfunction: results of a randomized controlled pilot trial. Psychooncology. 2013; 22:2354–2363.
Source: Breast Cancer: Basic and Clinical Research
Originally published xxxxx, 2016.